Pfizer Inc (PFE) Fair Value & Analysis
Healthcare · US · Market cap $148B
Pfizer Inc
PFE · US
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $20.67 to $24.87 (+20.3%) since Jun 23, 2026. Share price −4.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $22.51 – $28.55 · fair‑value band $17.41 – $37.49 · the $24.72 price screens below the $24.87 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pfizer Inc (PFE) currently trades at $24.72, while our model-based Fair Value estimate is $24.87 — implying the stock looks roughly 0.6% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Pfizer Inc generated revenue of $63.3B at a net margin of 11.8%. Revenue grew 5.4% year over year. It earns a return on equity of 8.3%. Net debt stands at $66.3B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pfizer Inc reported revenue of $62.6B in FY2025 versus $81.3B in FY2021, a compound −6.3%/yr. Reported net income was $7.8B in FY2025, compounding −23.0%/yr from FY2021.
Is PFE fairly valued? → Check now
Recent news
- UK Cardiovascular Clinical Trials Market Projected to Reach USD 892.2 Million by 2033
- Trump Financial Disclosure Shows 21,000 Trades in 2025
- $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income
- Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 159.68 MXN | -96% |
| Johnson & Johnson, JNJB34 | R$78.55 | R$12.18 | -84% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRK | $119.09 | $77.57 | -35% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pfizer Inc (PFE) undervalued?
What is the fair value of PFE?
What is the quality score of PFE?
What is the revenue of Pfizer Inc (PFE)?
What is the net profit margin of PFE?
Does Pfizer Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.